Bolt Biotherapeutics
BOLT on Nasdaq. Market value $12m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 23 funds in all.
Largest holders overall
- Sofinnova Investments$530,226
- Renaissance Technologies$379,706Added
- Vivo Capital$278,794
- Citadel Advisors$219,077Added
- T3 Companies$146,300
- Board of Trustees of The Leland Stanford Junior University$138,511
- Pfizer$133,832
- Lynx1 Capital Management LP$118,580
- Nano CAP New Millennium Growth Fund L P$105,875
- Geode Capital Management$73,622Cut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- Coastlands Capital Partners LPPassive investorat least 17.5%(filed with 3 related holders)Since 30 October 2026
- Renaissance Technologies LLCPassive investorat least 4.8%−0.3 pts(filed with 1 related holder)Since 30 September 2026
- Nan Fung Group Holdings LimitedPassive investorat least 4.6%−2.1 pts(filed with 10 related holders)Since 24 February 2026
- Vivo Panda Fund, L.P.Passive investorat least 3.8%(filed with 4 related holders)Since 31 December 2025
- TANG CAPITAL MANAGEMENT, LLCPassive investorat least 3.5%0.0 pts(filed with 5 related holders)Since 30 September 2025
| Holder | Stake | Since | |
|---|---|---|---|
Coastlands Capital Partners LP Passive investor | at least 17.5% (filed with 3 related holders) | 30 October 2026 | |
Renaissance Technologies LLC Passive investor | at least 4.8%−0.3 pts (filed with 1 related holder) | 30 September 2026 | |
Nan Fung Group Holdings Limited Passive investor | at least 4.6%−2.1 pts (filed with 10 related holders) | 24 February 2026 | |
Vivo Panda Fund, L.P. Passive investor | at least 3.8% (filed with 4 related holders) | 31 December 2025 | |
TANG CAPITAL MANAGEMENT, LLC Passive investor | at least 3.5%0.0 pts (filed with 5 related holders) | 30 September 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 2 insiders bought $5,594 of shares on the open market. 3 sold $128,281.
- Yonehiro GrantChief Operating OfficerSold
- Date
- 18 September 2026
- Shares
- 6,850
- Price
- $3.24
- Value
- $22,169
- Nemec SarahSenior VP, Finance and PAOSold
- Date
- 18 September 2026
- Shares
- 4,077
- Price
- $3.24
- Value
- $13,195
- Quinn William P.President, CEO and CFO, DirectorSold
- Date
- 18 September 2026
- Shares
- 9,132
- Price
- $3.24
- Value
- $29,555
- Yonehiro GrantChief Operating OfficerSold
- Date
- 17 September 2026
- Shares
- 4,909
- Price
- $3.32
- Value
- $16,290
- Nemec SarahSenior VP, Finance and PAOSold
- Date
- 17 September 2026
- Shares
- 2,922
- Price
- $3.32
- Value
- $9,696
- Quinn William P.President, CEO and CFO, DirectorSold
- Date
- 17 September 2026
- Shares
- 6,545
- Price
- $3.32
- Value
- $21,718
- Yonehiro GrantChief Operating OfficerSold
- Date
- 16 September 2026
- Shares
- 1,417
- Price
- $3.77
- Value
- $5,348
- Nemec SarahSenior VP, Finance and PAOSold
- Date
- 16 September 2026
- Shares
- 843
- Price
- $3.77
- Value
- $3,181
- Quinn William P.President, CEO and CFO, DirectorSold
- Date
- 16 September 2026
- Shares
- 1,889
- Price
- $3.77
- Value
- $7,129
- Nemec SarahSenior VP, Finance and PAOBought
- Date
- 5 June 2026
- Shares
- 509
- Price
- $3.88
- Value
- $1,973
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 18 September 2026 | Yonehiro Grant Chief Operating Officer | Sold | 6,850 | $3.24 | $22,169 |
| 18 September 2026 | Nemec Sarah Senior VP, Finance and PAO | Sold | 4,077 | $3.24 | $13,195 |
| 18 September 2026 | Quinn William P. President, CEO and CFO, Director | Sold | 9,132 | $3.24 | $29,555 |
| 17 September 2026 | Yonehiro Grant Chief Operating Officer | Sold | 4,909 | $3.32 | $16,290 |
| 17 September 2026 | Nemec Sarah Senior VP, Finance and PAO | Sold | 2,922 | $3.32 | $9,696 |
| 17 September 2026 | Quinn William P. President, CEO and CFO, Director | Sold | 6,545 | $3.32 | $21,718 |
| 16 September 2026 | Yonehiro Grant Chief Operating Officer | Sold | 1,417 | $3.77 | $5,348 |
| 16 September 2026 | Nemec Sarah Senior VP, Finance and PAO | Sold | 843 | $3.77 | $3,181 |
| 16 September 2026 | Quinn William P. President, CEO and CFO, Director | Sold | 1,889 | $3.77 | $7,129 |
| 5 June 2026 | Nemec Sarah Senior VP, Finance and PAO | Bought | 509 | $3.88 | $1,973 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Bolt Biotherapeutics’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Mar 2026, plus the 10-Q filed 13 Nov 2026 and 6 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“The Company has concluded that substantial doubt exists about its ability to continue as a going concern.”
Show the full paragraph
In October 2026, in connection with the acquisition of Prana, the Company completed a private placement financing (the “Private Placement”) through the sale of Series D Non-Voting Convertible Preferred Stock (the “Series D Preferred Stock”) and accompanying warrants, for aggregate gross proceeds of $ 120.0 million (see Note 12). Beginning nine months after closing date, a holder may, subject to the conditions, delivery deadlines and exceptions specified in the Certificate of Designation of Preferences, Rights and Limitations of Series D Non-Voting Convertible Preferred Stock (the “Certificate of Designation”), require cash settlement if the Company fails to deliver shares of common stock upon a properly requested conversion. The cash settlement amount is based on the average closing sale price of the Company's common stock over the ten trading days immediately preceding the applicable conversion date and is payable from legally available funds. Accordingly, based on the Company’s current operating plan, along with the Company’s history of operating losses, and given the potential risk of having to repurchase the Series D Preferred Stock, the Company’s current cash, cash equivalents and marketable securities may not be sufficient to fund the Company’s ongoing operations for a period of at least twelve months from the issuance date of these unaudited condensed consolidated financial statements. The Company has concluded that substantial doubt exists about its ability to continue as a going concern.
From the 10-Q filed 13 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.